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Histamine regulates release of neurotransmitters such as dopamine, serotonin, gamma-aminobutyric
acid (GABA), glutamate and also is involved in several functions in central nervous system (CNS). It has
been shown that histamine participates in disorders like seizure. It has been well documented that
morphine dose-dependently induces anti or proconvulsant effects. In the current study, we ﬁrstly
showed that morphine (1 mg/kg) exerts anticonvulsant effects which signiﬁcantly reversed by naltrex-
one administration. Secondly, we determined seizure threshold for H1 and H3 receptors agonists and
antagonists in mouse model of pentylenetetrazole (PTZ)-induced clonic seizures. Our results showed that
activation of H1 receptors by 2-(2-Pyridyl)-ethylamine exerts anticonvulsant properties while inhibition
of H1 receptors by pyrilamine maleate induced proconvulsant effects. Furthermore, we showed that
immepip dihydrobromide, a H3 receptor agonist, increased seizure susceptibility to PTZ whereas thio-
peramide, a H3 receptor antagonist increased seizure threshold. We also revealed that pretreatment with
morphine potently reversed the effects of histaminergic system on seizure threshold suggesting the
involvement of opioid system in alteration of seizure threshold by histaminergic drugs.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
Histamine [2-(4-imidazolyl)-ethylamine], an endogenous bio-
genic amine, mediates pleiotropic functions in the central nervous
system (CNS) (Fernandez-Novoa and Cacabelos, 2001). Histami-
nergic neurons are located in tuberomamillary nucleus of hy-
pothalamus and projects to practically all major brain regions
(Haas and Panula, 2003). This neurotransmitter has been im-
plicated in regulation of several CNS activities such as cognition,
arousal, circadian rhythms, synaptic plasticity, pain perception,
stress, anxiety, and neuroendocrine regulation (Brown et al.,ne Research Center, Tehran
ehran, Iran.2001). Evidence indicates histamine modulates the release of
other neurotransmitters such as dopamine, serotonin, nor-
epinephrine and gamma-aminobutyric acid (GABA) (Flik et al.,
2015). Since histamine participates in variety of brain pathologies,
it has been suggested that histaminergic system would be an ap-
propriate therapeutic target for treatment of neuropathic pain,
sleep-wake disorders, attention deﬁcit hyperactivity disorder,
Alzheimer's disease, Parkinson's disease, schizophrenia, migraine
and epilepsy (Alstadhaug, 2014; Gemkow et al., 2009; Passani and
Blandina, 2011).
Clinical and preclinical studies have suggested the possible
involvement of histaminergic system in seizure disorders (Stark,
2003). In this regard, previous research demonstrated that in-
creased level of central histamine acts as an endogenous antic-
onvulsant agent and exerts an important inhibitory effect during
seizure episodes (Bhowmik et al., 2012). Using animal models of
electrically/chemically-induced seizure, it has been shown that
activation of the histaminergic system, mainly through H1
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Tuomisto and Tacke, 1986). However, applying H1 receptor an-
tagonists exhibited proconvulsant effects in animal studies (Cer-
minara et al., 2013). Moreover, there are pieces of evidence in-
dicating the involvement of H3 receptors in the seizure activity
(Harada et al., 2004; Sadek et al., 2014). A number of investigations
have revealed that H3 receptor antagonists not only mitigate the
severity of epileptic symptoms but protect neurons against sei-
zure-associated neurotoxicity through enhancing the release of
histamine, GABA and also, histidine decarboxylase activity
(Bhowmik et al., 2012; Devi et al., 2011).
On the other hand, evidence suggests that opioids exert both
proconvulsant and anticonvulsant effects in different animal
models of seizure (Homayoun et al., 2002b; Lauretti et al., 1994).
While low doses of morphine have been reported to reduce the
seizure susceptibility to picrotoxin, bicuculline and pentylenete-
trazol (PTZ), higher doses induce proconvulsant effects that in-
dicating the biphasic effects of morphine on seizure threshold
(Frenk, 1983; Lauretti et al., 1994). Considering that opioid re-
ceptors possess seizure-modulating properties, they may have
functional interactions with other receptor classes involved in
seizure activity (Shafaroodi et al., 2004). Considering that both
opioid and histamine receptors share physiological properties such
as anti-nociception, a possible interaction may exist between these
two classes of receptors in controlling seizures. The purpose of the
current study is to examine whether opioid system may play a role
in mediating the effects of histamine H1 and H3 receptor agonists/
antagonists on seizure susceptibility to PTZ.2. Materials and methods
2.1. Animals
Male NMRI mice weighing 2773 g (Pasteur Institute, Tehran,
Iran) were used in this study. Animals were housed in standard
polycarbonate cages (4–5 mice per cage) and under standard la-
boratory conditions (12-h light/dark cycle, temperature (2271 °C)
and free access to food and water). All behavioral experiments
were performed between 10:00 a.m. and 13:00 p.m. All proce-
dures in this study were carried out in accordance with the Na-
tional Institutes of Health (NIH) Guide for the Care and Use of
Laboratory Animals (NIH Publication no. 80-23) and institutional
guidelines for animal care and use (Department of Pharmacology,
School of Medicine, TUMS). Each mouse underwent treatment
only once and also each treatment group was consisted of
8 animals.
2.2. Drugs
The drugs used in this study were as follows: morphine sulfate,
pentylenetetrazole (Sigma, U.K.), naltrexone, 2-(2-Pyridyl)-ethyla-
mine, pyrilamine maleate, immepip dihydrobromide and thio-
peramide maleate (Sigma, St Louis, MO, USA). All drugs were
dissolved in 0.9% saline in a volume of 10 ml/kg. In order to assess
clonic seizures in experimental animals, PTZ was administered
intravenously (0.5%, i.v.) and all other drugs were administered
intraperitoneally (i.p.). Doses of each drug were selected based on
our previous and pilot studies (Honar et al., 2004).
2.3. Treatment
Experiment 1 examined the effect of morphine (1 mg/kg) on
clonic seizure threshold. Animals in this experiment received
morphine 30 min before PTZ administration.
In experiment 2 we examined the effect of naltrexone (10 mg/kg) along with morphine (1 mg/kg) on clonic seizure threshold.
Animals in this trial received naltrexone 15 min prior to morphine
injection and 45 min before the administration of PTZ.
Experiment 3 examined the effect of 2-(2-Pyridyl)-ethylamine
(H1 agonist, 5 mg/kg) alone (30 min before the test) or along with
morphine (1 mg/kg, 15 min prior to 2-(2-Pyridyl)-ethylamine) on
seizure threshold.
In experiment 4 effect of pyrilamine maleate (H1 antagonist,
10 mg/kg) alone (30 min before the test) or along with morphine
(1 mg/kg, 15 min before pyrilamine maleate) on seizure threshold
was determined.
Experiment 5 was designed to examine the effect of immepip
dihydrobromide (H3 agonist, 10 mg/kg) alone (30 min before the
test) or in combination with morphine (1 mg/kg, 15 min prior to
immepip dihydrobromide) on seizure threshold.
Experiment 6 examined the effect of thioperamide (H3 an-
tagonist, 10 mg/kg) alone (30 min before the test) or along with
morphine (1 mg/kg, 15 min before thioperamide maleate) on sei-
zure threshold.
2.4. Determination of seizure threshold
We assessed the seizure threshold using the method that was
previously described in our previous studies (Amiri et al., 2014;
Amini-Khoei et al., 2015). To determine the clonic seizure
threshold, we inserted a 30-gauge butterﬂy needle into the lateral
tail vein of mice. The needle was then ﬁxed to the tail by a piece of
adhesive tape. With the mouse moving freely, the PTZ solution
(0.5%) was slowly infused into the tail vein at a constant rate of
1 ml/min, using an infusion pump (NE 1000, New Era Pump Sys-
tem, Inc.), which was connected to the dental needle by poly-
ethylene tubing. Infusion was halted when forelimb clonus fol-
lowed by full clonus of the body (began with running and then loss
of righting ability) was observed. The minimal dose of PTZ (mg/kg
of mice weight) needed to induce general clonus was recorded as
an index of clonic seizure threshold. In this regard, the seizure
threshold is dependent on PTZ dose administered and time-
related.
2.5. Statistics
The one-way analysis of variance (ANOVA) followed by Tukey's
post-hoc test was used to analyze the data. Values are expressed as
mean7S.E.M., a value of Po0.05 was considered as statistically
signiﬁcant in all experiments.3. Results
3.1. Effects of morphine and naltrexone on seizure threshold
As shown in Fig. 1A, administration of morphine (30 min before
the test) signiﬁcantly increased seizure threshold in animals
(**Po0.01). In addition, pretreatment with naltrexone (15 min
prior to morphine treatment) signiﬁcantly decreased seizure
threshold (##Po0.01). Furthermore, naltrexone by its own had no
effect on seizure threshold (P40.05).
3.2. Effect of 2-(2-Pyridyl)-ethylamine (H1 agonist) on the PTZ-in-
duced seizures
Fig. 1B shows the effect of morphine pretreatment on the an-
ticonvulsant effect of 2-(2-Pyridyl)-ethylamine against PTZ-in-
duced seizures. Administration of 2-(2-Pyridyl)-ethylamine sig-
niﬁcantly increased the seizure threshold in comparison with
saline- treated controls (*Po0.05). Moreover, morphine
Fig.1. Effects of different treatments on seizure threshold in PTZ model of clonic seizures in mice: (A) Effects of morphine (Mor) and naltrexone (NTX) treatments on seizure
threshold. (B) Effects of 2-(2-Pyridyl)-ethylamine (PEA) and morphine on seizure threshold. (C) Effects of pyrilamine maleate (PYR) and morphine on seizure threshold.
(D) Effects of immepip dihydrobromide (IMM) and morphine on seizure threshold. (E) Effects of thioperamide maleate (THIO) and morphine on seizure threshold. Data are
expressed as mean7S.E.M. (n¼8) and were analyzed by one-way ANOVA and Tukey's post-hoc test. *Po0.05 and **Po0.01 compared with saline-treated controls in each
ﬁgure. ##Po0.01 compared with morphine treated group in Fig. 1A. @@@Po0.001 compared with PEA treated group in Fig. 1B. $Po0.05 compared with PYR treated group in
Fig. 1C. &Po0.05 compared with IMM treated group in Fig. 1D. þPo0.05 compared with THIO treated group in Fig. 1E.
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ethylamine (@@@Po0.001).
3.3. Effect of pyrilamine maleate (H1 antagonist) on the PTZ-induced
seizures
Fig. 1C shows the effect of morphine pretreatment on the
proconvulsant effect of pyrilamine maleate against PTZ-induced
seizures. Administration of pyrilamine maleate signiﬁcantly de-
creased the seizure threshold in comparison with saline-treatedcontrols (*Po0.05). As shown in Fig. 1C, morphine pretreatment
signiﬁcantly reversed the proconvulsant effect of pyrilamine
maleate ($Po0.05).
3.4. Effect of immepip dihydrobromide (H3 agonist) on the PTZ-in-
duced seizures
As shown in Fig. 1D, administration of immepip dihydro-
bromide signiﬁcantly decreased the seizure threshold in compar-
ison with saline-treated controls (*Po0.05). Furthermore,
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when compared with IMM treated group (&Po0.05).
3.5. Effect of thioperamide maleate (H3 antagonist) on the PTZ-in-
duced seizures
As shown in Fig. 1E, administration of thioperamide maleate
signiﬁcantly increased the seizure threshold in comparison with
saline-treated controls (**Po0.01). Also, morphine pretreatment
reversed the anticonvulsant effect of thioperamide maleate
(þPo0.05).4. Discussion
Results of the present study revealed that H1 and H3 receptors
play a role in seizure susceptibility to PTZ and also, opioid system
is involved in their effects. In contrast to H3 receptors, activation of
H1 receptors by its agonists produced anticonvulsant effect and
application of H1 antagonists led to a decrease in seizure thresh-
old. In addition, modulatory effects of morphine on histaminergic-
induced alterations in seizure threshold suggest the interaction
between opioid and histaminergic system in seizure susceptibility
to PTZ.
While vast majority of investigations in epilepsy have focused
on inhibitory and excitatory neurotransmissions, role of other
contributing neurotransmitters, such as histamine and its inter-
actions with other neurotransmission systems have not been
studied well. Evidence indicates that histaminergic system has
many interactions with excitatory and inhibitory neurotransmis-
sion. Once couples to GABAergic and glutaminergic systems, his-
tamine is able to regulate histaminergic activity through interac-
tions with GABAA, GABAB and NMDA receptors. Moreover, hista-
mine inhibits the release of several neurotransmitters, such as
GABA, glutamate, dopamine serotonin, noradrenaline and acet-
ylcholine via H3 receptors (Brown et al., 2001; Lintunen et al.,
2005). There are pieces of evidence suggesting that unlike H1 re-
ceptor antagonists, activation of the central histaminergic system
by H1 receptor agonists positively modiﬁes seizure activity (Kuk-
ko-Lukjanov et al., 2012; Miyata et al., 2011).
Our results were consistent with these studies that adminis-
tration of 2-(2-Pyridyl)-ethylamine led to an increase in seizure
susceptibility to PTZ while pyrilamine maleate produced pro-
convulsant effect. Considering that H3 receptors are inhibitory
auto-receptors in histaminergic neurons, previous studies have
shown that H3 receptor antagonists are able to mitigate seizure
susceptibility by increasing the release of histamine in brain
(Bhowmik et al., 2012; Trenité et al., 2013). In this context, thio-
peramide, a selective H3 receptor antagonist, has been reported to
decrease seizure vulnerability to PTZ via increasing the en-
dogenous histamine levels in brain (Vohora et al., 2000). In
agreement with previous investigations, our results corroborated
the anticonvulsant properties of H3 receptor antagonists that mice
treated with immepip dihydrobromide exhibited more sensitivity
to convulsing effects of PTZ while treating animals with thioper-
amide induced an anticonvulsant effect. In this context, it has been
reported that H3-receptor agonists or H1-receptor antagonists
increase seizure susceptibility in different models of seizures in-
cluding amygdaloid kindling, maximal electroshock, picrotoxin
and pentylenetetrazol-induced-induced seizures (Sturman et al.,
1994; Vohora et al., 2001).
On the other hand, components of opioid system have been
widely distributed in CNS and play an important role in regulation
of many behavioral and cognitive processes such as pain, neuro-
transmission and seizure activity (Akil et al., 1984; Khan et al.,
2015). Using different experimental models of seizures, it has beenshown that opioids dose- dependently exert anticonvulsant and
proconvulsant effects (Gooshe et al., 2015; Homayoun et al.,
2002b). Surprisingly, in contrast to higher doses of morphine,
lower doses of morphine have anticonvulsant properties (Ho-
mayoun et al., 2002a). Morphine in high doses induces excitation
and causes myoclonus seizures (Gregory et al., 1992; Hagen and
Swanson, 1997). Previous studies suggest that proconvulsant effect
of morphine may be associated with production of 3-glucuronide
(a morphine metabolite) (Hemstapat et al., 2003), or nitric oxide
(Khavandgar et al., 2002). Further investigations have also sug-
gested that multiple receptor systems such as adrenergic and
glutamatergic receptors (Homayoun et al., 2002a; Schroeder et al.,
1998) or inhibition of GABAergic neurotransmission (Werz and
MacDonald, 1982) are involved in triggering opioid-induced
seizures.
Focusing on histaminergic system, past studies demonstrated
that histaminergic system mediates some of the central effects of
morphine and acute treatment with morphine enhances the
turnover of neuronal histamine (Karadag et al., 2000). A study by
Karadag et al. (1996) has recently showed that H1-receptor an-
tagonists and naloxone are able to antagonize the anticonvulsant
effect of morphine. Moreover, it has been reported that phos-
pholipase C and calcium-linked transduction systems are related
to opioid receptor activation which consequently lead to de-
granulation of mast cell and histamine release (Rehni et al., 2010).
Results of the current work showed that Co-administration of
morphine with both H1 and H3 agonists/antagonists reversed their
effects on seizure susceptibility to PTZ indicating the interaction
between opioid system and histaminergic system in mediating the
seizure activity. Also, these data suggests the involvement of
opioid system in different effects of histaminergic system on sei-
zure susceptibility to PTZ as a GABAA antagonist (Di Capite and
Parekh, 2009; Liu and Gintzler, 2006; LÜ et al., 2013). Furthermore,
it has been reported that opioid receptor-induced seizures is cor-
related with a signiﬁcant increase in histamine release that may
mediate the proconvulsant properties of morphine (Zhu-Ge et al.,
2007). In this regard, Rehni et al. demonstrated that pro-con-
vulsant effect of amisulpride may be associated with opioid sys-
tem-induced activation of histamine receptors. They also showed
that pretreatment with a H1 blocker or a mast cell stabilizer sig-
niﬁcantly attenuated the amisulpride-induced seizures in mice
(Rehni et al., 2011).5. Conclusion
In conclusion, results of our study showed that pretreatment
with morphine potently reversed the effects of histaminergic
system (H1 and H3) on seizure susceptibility to PTZ in mice. Also,
our results suggest that opioid system is partially involved in the
effects of histamine on seizure activity.References
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